Journal
PULMONARY PHARMACOLOGY & THERAPEUTICS
Volume 21, Issue 1, Pages 112-114Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pupt.2007.01.003
Keywords
5-Hydroxytryptamine; Cohort; Pulmonary arterial hypertension; Serotonin; Six-minute walk testing
Categories
Funding
- NCRR NIH HHS [RR00645, M01 RR000645-331023, M01 RR000645] Funding Source: Medline
- NHLBI NIH HHS [K23 HL067771, HL072739, L30 HL086095, K23 HL067771-04, HL67771, K23 HL067771-01, HL082895, T32 HL072739, K23 HL067771-03, R01 HL082895, K23 HL067771-02, K23 HL067771-06, K23 HL067771-05] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL067771, R01HL082895, T32HL072739] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Serotonin (5-HT) has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We hypothesized that plasma 5-HT Would be elevated in PAH related to associated conditions. We performed a prospective cohort study of 21 patients with PAH Undergoing initial right heart catheterization and 6 healthy controls. Platelet-free plasma 5-HT levels were similar in patients with idiopathic PAH, PAH related to associated conditions, and healthy controls. Higher 5-HT levels correlated with increased six-minute walk distance (r = 0.55, p = 0.04). These data suggest that plasma 5-HT levels are normal in PAH. Plasma 5-HT may therefore not be a useful biomarker in this condition. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
